Key Metrics
CiteScore 

5.6
Eigenfactor 

0.001 - 0.005
Impact Factor 

< 5
SJR 

Q1Pharmacology

SNIP 

0.93
Recommended pre-submission checks
Powered by 

Topics Covered on Cardiovascular Drugs and Therapy
Cardiovascular Drugs and Therapy Journal Specifications
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1987 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Cardiovascular Drugs and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Cardiovascular Drugs and Therapy
Interpreting Short-Term Safety and Albuminuria in the FINE-TURK Registry.
- 23 Oct 2026
- Cardiovascular drugs and therapy
Epicardial Versus Circulating Adiponectin: An Unresolved Distinction in Liraglutide's Anti-Arrhythmic Mechanism.
- 17 Oct 2026
- Cardiovascular drugs and therapy
MiR‑18a‑5p Serves as a Diagnostic and Prognostic Biomarker and Attenuates Hypoxia‑Induced Cardiac Microvascular Endothelial Injury by Targeting the HIF1A/NF‑κB Pathway in Chronic Heart Failure.
- 15 Oct 2026
- Cardiovascular drugs and therapy
Rethinking Plaque Stabilization with Evolocumab in Diabetes: Methodological Considerations from the YELLOW III Trial.
- 14 Oct 2026
- Cardiovascular drugs and therapy
MSCs-derived Exosomal miRNA-335-5p Alleviates Apoptosis and Inflammation in Myocardial Infarction by Inhibiting BCL2L11.
- 14 Oct 2026
- Cardiovascular drugs and therapy
Gut Microbiota and Its Metabolites in the Prognosis of Coronary Heart Disease: A Systematic Review and Mechanistic Insights
- 9 Oct 2026
- Cardiovascular Drugs and Therapy
Interpreting Short-Term Safety and Albuminuria in the FINE-TURK Registry.
- 23 Oct 2026
- Cardiovascular drugs and therapy
Epicardial Versus Circulating Adiponectin: An Unresolved Distinction in Liraglutide's Anti-Arrhythmic Mechanism.
- 17 Oct 2026
- Cardiovascular drugs and therapy
MiR‑18a‑5p Serves as a Diagnostic and Prognostic Biomarker and Attenuates Hypoxia‑Induced Cardiac Microvascular Endothelial Injury by Targeting the HIF1A/NF‑κB Pathway in Chronic Heart Failure.
- 15 Oct 2026
- Cardiovascular drugs and therapy
Rethinking Plaque Stabilization with Evolocumab in Diabetes: Methodological Considerations from the YELLOW III Trial.
- 14 Oct 2026
- Cardiovascular drugs and therapy
MSCs-derived Exosomal miRNA-335-5p Alleviates Apoptosis and Inflammation in Myocardial Infarction by Inhibiting BCL2L11.
- 14 Oct 2026
- Cardiovascular drugs and therapy
Gut Microbiota and Its Metabolites in the Prognosis of Coronary Heart Disease: A Systematic Review and Mechanistic Insights
- 9 Oct 2026
- Cardiovascular Drugs and Therapy